SMAD3 and atrial fibrillation: Baulier et al. [125] showed that AF-MSCs can treat renal fibrosis in animal models, and this effect may be associated with AF-MSC-mediated enhancement of glomerular and tubular function through the TGF-β/Smad3 pathway, effectively improving renal fibrosis.